Recent Updates
Recently added Catalysts

Montelukast chewable

Phase 1

Asthma | Small molecule | Respiratory |GSK plc|Last Updated: Jun 15, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment32

FDA Designations

No designations recorded

Clinical trial landscape

Montelukast chewable · 1 trial · 1 indication

Phase 1 1
NCT01863654Bioequivalence Study of Montelukast 5 mg ChewableAsthma
COMPLETED32 Analytics
PHASE1COMPLETED
Bioequivalence Study of Montelukast 5 mg Chewable
AsthmaUnlock trial analytics

Study Endpoints

Primary Endpoints

Peak Plasma Concentration (CMAX) of montelukast
0.0, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 15.0, 18, and 22 hours postdosage

Pharmacokinetics

Area under the plasma concentration versus time curve (AUC) of montelukast
0.0, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 15.0, 18, and 22 hours postdosage

Pharmacokinetics

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
A(reference)/B(test)EXPERIMENTALinitial administration of reference and cross-over to test
B(test)/A(reference)EXPERIMENTALinitial administration of test and cross-over to reference

Interventions

NameTypeDescription
Montelukast 5 mg chewable tabletsDRUGReference product
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: Free will participation according to Mexican regulation, Helsinki Declaration, and Good Clinical Practice. Healthy, between 18 and 50 years. Body Mass Index between 19 and 27 In good health by complete medical history and laboratory tests. Blood pressure 130-90/ 90-60 mm Hg; he...

Unlock Eligibility Criteria